Sihuan Pharmaceutical Holdings Group Ltd
https://www.sihuanpharm.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sihuan Pharmaceutical Holdings Group Ltd
China Biotech IPOs Remain In Deep Freeze, Hong Kong Fares Better
Amid stricter regulatory reviews of applications for IPOs across all sectors, such offerings in biotech have been in hiatus on the Chinese mainland in 2024 to date. Meanwhile, three bioventures raised a combined $217.8m as they floated on the Hong Kong Stock Exchange in the first half.
Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022
Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- KBP BioSciences Pharmaceutical Technical Co., Ltd.
- Shandong Xuanzhu Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice